FDA-cleared profile

Quantra

HOLOGIC, INC. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.

Clinical role
Breast-density categorization and adjunct radiologist assessment.
Images and patients
Mammography/DBT · Breast; mammographic breast-density composition
Key limitation
Keep in mind: The FDA labeling describes Quantra as additional information and not a diagnostic aid. Use remains limited to supported digital mammography images and requires radiologist assessment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast; mammographic breast-density composition Input: Digital mammographic images from supported digital breast X-ray systems.
  • Who uses it?Intended users: Radiologists and qualified breast-imaging professionals.
  • What does the software produce?Output: A breast-density category or result per subject for radiologist review.
  • What is its most important limitation?Key limitation: The FDA labeling describes Quantra as additional information and not a diagnostic aid. Use remains limited to supported digital mammography images and requires radiologist assessment.

Clinical takeaway. Clinical role: Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.

Evidence takeaway. Evidence from the reviewed source record: K163623 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for Quantra 2.2. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Quantra 2.2 analyzes digital breast X-ray images and categorizes breast density to provide additional information for a radiologist's assessment.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Breast-density categorization and adjunct radiologist assessment.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Digital mammographic images from supported digital breast X-ray systems.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
A breast-density category or result per subject for radiologist review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Mammography and breast-imaging reporting workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists and qualified breast-imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling describes Quantra as additional information and not a diagnostic aid. Use remains limited to supported digital mammography images and requires radiologist assessment.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
K163623 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for Quantra 2.2. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K163623 FDA decision material establishes the labeled use, workflow, inputs, outputs, and limitations for Quantra 2.2. No exact-submission clinical performance metric is promoted without a complete source table and version-scoped endpoint.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K163623 FDA evidence package for Quantra

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationBreast; mammographic breast-density composition
  • Scopeexact submission
  • Tested versionQuantra 2.2
  • IndependenceSponsor or vendor study

K163623

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K163623 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Digital mammographic images from supported digital breast X-ray systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K163623: Quantra

  2. Routing

    Source context, not route validation: The FDA package describes digital mammographic image input and a density result used in the radiologist's reporting workflow.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K163623: Quantra

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: A breast-density category or result per subject for radiologist review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K163623: Quantra

  5. Viewer/worklist/report

    Unresolved route: A breast-density category or result per subject for radiologist review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K163623: Quantra

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA package describes digital mammographic image input and a density result used in the radiologist's reporting workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Security
Hologic's Breast and Skeletal Products Cybersecurity page states patch validation for Hologic Breast and Skeletal Health systems, MDS2 forms availability, and published security advisories with product impact analyses (including Libwebp, MOVEit, Log4j and Axeda advisories).
  • Product family
  • Checked 2026-10-26

Vendor statement, not an attestation. Page scope is Hologic's Breast and Skeletal Health division; this entry is a mammography/DBT product within that division. Exact-release scope is not established.

Training
Use by radiologists and qualified breast-imaging professionals. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K163623.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K163623.

exact submission · checked 2026-09-04

Deployment boundary

The exact public deployment boundary is incomplete; confirm hosting, data flow, availability, upgrades, security, service, and downtime locally.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes digital mammographic image input and a density result used in the radiologist's reporting workflow.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K163623.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K163623
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Breast; mammographic breast-density composition
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2017-10-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. Breast-density records test Quantra 2.0 or omit a version rather than Quantra 2.2; the other PubMed and trial records concern the unrelated HemoSonics Quantra coagulation product. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K163623: Quantra

    U.S. Food and Drug Administration - Published 2017-10-20 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Quantra model card (K163623)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Hologic: Breast & Skeletal Products Cybersecurity

    Hologic - Accessed 2026-10-26

    Scope: security

Research history

  1. K163623 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250754

cmAngio® (V1.6)

CureMetrix, Inc.

Authorized purpose: cmAngio (V1.6) processes screening mammograms to aid a qualified interpreting physician in the manual process of identifying breast arterial calcification. It detects the presence or absence of breast arterial calcifications at the study and breast level in full-field digital mammography and digital breast tomosynthesis screening mammograms and marks BAC segments on image thumbnails for localization.

Modality
Mammography/DBT
Anatomy
Female breasts; breast arterial calcification
Decision
2025-04-10
FDA-cleared K232367

cmAngio® V1.0

CureMetrix, Inc.

Authorized purpose: cmAngio processes screening FFDM and DBT mammograms to detect presence or absence of breast arterial calcifications at study and breast level and mark segments for qualified interpreting-physician review; it is not primary breast-cancer interpretation or a standalone diagnostic or treatment decision tool.

Modality
Mammography/DBT
Anatomy
Breast; breast arterial calcifications
Decision
2023-10-05
FDA-cleared K211431

breastscape v1.0

Olea Medical

Authorized purpose: Visualization, analysis, reporting, lesion measurement, kinetic assessment, and MR-guided breast interventional planning; when interpreted by a skilled physician, information may support screening, diagnosis, and intervention planning, but patient management must not rely solely on the results.

Modality
Mammography/DBT
Anatomy
Breast lesions and breast morphological landmarks including nipple, chest, and skin borders.
Decision
2021-08-02
FDA-cleared K142037

QUANTRA

HOLOGIC, INC.

Authorized purpose: Quantra version 2.1 calculates volumetric and area breast-density measures and density categories from supported digital mammography images as an adjunct, not a diagnostic result.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2014-10-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history